The role of new ABC transporter in anti-cancer drug resistance in hepatoma.
Project/Area Number |
11670547
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Gastroenterology
|
Research Institution | Kansai Medical University |
Principal Investigator |
NAKAHASHI Yoshitsugu Kansai Medical University Medicine Instructor, 医学部, 助手 (70247930)
|
Co-Investigator(Kenkyū-buntansha) |
MIYAZAKI Hiroaki Kansai Medical University Medicine Instructor, 医学部, 助手 (30268370)
NAITOH Yuji Kansai Medical University Medicine Assistant Professor, 医学部, 講師 (30198014)
|
Project Period (FY) |
1999 – 2000
|
Project Status |
Completed (Fiscal Year 2000)
|
Budget Amount *help |
¥3,300,000 (Direct Cost: ¥3,300,000)
Fiscal Year 2000: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 1999: ¥2,400,000 (Direct Cost: ¥2,400,000)
|
Keywords | Resistance to anti-cancer drug / ABC transporter / Hepatoma |
Research Abstract |
1.Expression of anthracycline resistance-associated protein (ARA) and multidrug resistance-associated protein 6 (MRP6) RNA in hepatoma cell lines. ARA and MRP6 were detected by RT-PCR and expressed by Northern blot analysis in HepG2, Huh7, PLC/PRF/5, HCC-T and HCC-M cell lines. 2.Increased expression of ARA and MRP6 by anti-cancer drugs. HepG2, Huh7, PLC/PRF/5 were treated with 10ng/ml epirubicin for 7 days. ARA and MRP6 were not induced in these cell lines for 7 days. 3.Amplification of ARA and MRP6 gene in anti-cancer resistant hepatoma cell lines. We established 100ng/ml epirubicin-resistant Huh7 cell line. Southern blot analysis indicated that both of ARA and MRP6 gene were amplified in this Huh7 cell line. 4.Modulation of anti-cancer drug resistance by xenobiotics excreted through MRP Glycyrrhizin is known to be the MRP2 substrate. Glycyrrhizin enhanced anti-cancer effect of epirubicin when HepG2, Huh7 and PLC/PRF/5 were treated with epirubicin and glycyrrhizin.
|
Report
(3 results)
Research Products
(6 results)